- Home
- » Tags
- » Cefiderocol
Top View
- Cephalosporins: a Focus on Side Chains and -Lactam Cross-Reactivity
- Shionogi Briefing Document
- Cefiderocol: Discovery, Chemistry, and in Vivo Profiles of a Novel
- Stability of Cefiderocol Against Clinically-Significant Broad-Spectrum Oxacillinases
- PRODUCT CATALOGUE 2021-2022 IVD Solutions Through Partnership
- Fetcroja, INN-Cefiderocol
- VAE) for Use in Adult Locations Only
- Activity of the Novel Siderophore Cephalosporin Cefiderocol Against Multidrug-Resistant Gram-Negative Pathogens
- Guide to Antimicrobial Chemotherapy (PDF)
- 2019 Antibacterial Agents in Clinical Development
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against
- Cefiderocol (Fetcroja ®) for the Treatment of Infections Due to Aerobic Gram-Negative Organisms in Adults with Limited Treatment Options”
- FETROJA (Cefiderocol) for Injection, for Intravenous Use ------WARNINGS and PRECAUTIONS------Initial U.S
- Antimicrobial Resistance Benchmark 2018
- Mode of Action of Cefiderocol, a Novel Siderophore Cephalosporin, Active
- Antibiotics in the Clinical Pipeline in October 2019
- New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives
- Cefiderocol) for Injection, for Intravenous Use Limited Or No Alternative Treatment Options for the Treatment of Cuti
- Center for Drug Evaluation and Research
- Compassionate Use of Cefiderocol to Treat a Case of Prosthetic Joint
- Successful Treatment of Infective Endocarditis Due to Pandrug‑Resistant Klebsiella Pneumoniae with Ceftazidime‑Avibactam and Aztreonam Majed F
- Standard and High Dose Antibiotic Dosing Regimens
- Cefiderocol in Critically Ill Patients with Multi-Drug Resistant
- Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
- Cefiderocol and Other Beta-Lactam Antibacterial Drugs Or FETROJA
- Antibiotic Disc Antibiotic Discs for Susceptibility Tests
- Restricted Antimicrobials Requiring Ast Approval in Patients on Adult Services
- Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-To-Treat Resistance
- Bacterial Infections
- Urinary Tract Infection in Women - Complicated (1 of 13)
- Ceftazidime/Avibactam Allergan/Pfizer Approved February 25, 2015 EMA: June 2016 6
- Antibiotics 201: Gram- Negatives Disclosures
- Susceptibility Testing Is Key for the Success of Cefiderocol